How does EVQLV’s technology work?

Jun 1, 2020 | Blog | 0 comments

Daniel Gigante

This is a clip from our event with BioIDEA: Biotech vs COVID-19. Our CEO, Andrew Satz, explains how our technology works, with specific attention to our work on COVID-19. Give it a listen below (transcription beneath video).


We use nearly a hundred billion data points across a wide range of biological data. That includes gene sequences, biological structures, biophysical properties and more. And we integrate all that data and then apply our evolutionary algorithms and computational tests. This all gives our artificial intelligence engine the ability to make statistically informed decisions.

To be clear, this process is not about replacing the work of scientists in the lab. Instead, it’s about accelerating and augmenting the decision-making being made by life scientists as they work on drugs for the coronavirus.

We’re driven, at our company, to use computational technology to support each key member in the drug discovery and development process, in order to prevent failure in the lab, in animal tests, or in clinical trials.

Today, our technology works by taking an existing antibody sequence. For example, an antibody that targets the spike of the coronavirus that may have come from an animal or a patient that recovered from the coronavirus. We then apply our proprietary evolutionary algorithms to generate evolutionary mutated daughters of those antibodies. By taking those antibodies that we know target the coronavirus and applying our algorithms, we can generate variants that could be used in larger segments of the population.


Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology

Demystifying AI In Pharma

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

How Our Algorithm Models the Drug Discovery Process

Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

Pin It on Pinterest